J&J Longs For Cypher Longevity, May Enjoy 15-Month Monopoly In Japan
This article was originally published in The Gray Sheet
Executive Summary
Cordis aims to expand the U.S. shelf life of its Cypher sirolimus-eluting stent after resolving manufacturing issues cited by FDA in an April 2004 warning letter